Loading...

UCSF Coronavirus Response: UCSF is partnering with public agencies to address the rapidly evolving outbreak and protect our communities. The UCSF COVID-19 Resources Website provides guidance and information for our patients, faculty, staff, trainees and learners.

Julia Rohrberg, PhD

Title(s)Associate Specialist, Cell and Tissue Biology
SchoolSchool of Dentistry
Phone415-476-4187
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Rohrberg J, Van de Mark D, Amouzgar M, Lee JV, Taileb M, Corella A, Kilinc S, Williams J, Jokisch ML, Camarda R, Balakrishnan S, Shankar R, Zhou A, Chang AN, Chen B, Rugo HS, Dumont S, Goga A. MYC Dysregulates Mitosis, Revealing Cancer Vulnerabilities. Cell Rep. 2020 Mar 10; 30(10):3368-3382.e7. PMID: 32160543.
      View in: PubMed
    2. Shah KN, Bhatt R, Rotow J, Rohrberg J, Olivas V, Wang VE, Hemmati G, Martins MM, Maynard A, Kuhn J, Galeas J, Donnella HJ, Kaushik S, Ku A, Dumont S, Krings G, Haringsma HJ, Robillard L, Simmons AD, Harding TC, McCormick F, Goga A, Blakely CM, Bivona TG, Bandyopadhyay S. Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer. Nat Med. 2019 01; 25(1):111-118. PMID: 30478424.
      View in: PubMed
    3. Sahasrabudhe P, Rohrberg J, Biebl MM, Rutz DA, Buchner J. The Plasticity of the Hsp90 Co-chaperone System. Mol Cell. 2017 Sep 21; 67(6):947-961.e5. PMID: 28890336.
      View in: PubMed
    4. Horiuchi D, Camarda R, Zhou AY, Yau C, Momcilovic O, Balakrishnan S, Corella AN, Eyob H, Kessenbrock K, Lawson DA, Marsh LA, Anderton BN, Rohrberg J, Kunder R, Bazarov AV, Yaswen P, McManus MT, Rugo HS, Werb Z, Goga A. PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression. Nat Med. 2016 11; 22(11):1321-1329. PMID: 27775705.
      View in: PubMed
    5. J. Rohrberg, A. Corella, L. Starnes, A. Goga. 367: Elucidating the synthetic lethal effect of CDK inhibition in triple negative breast cancer. European Journal of Cancer. 2014 Jul 1; 50:s88.
      View in: Publisher Site
    6. Peschek J, Braun N, Rohrberg J, Back KC, Kriehuber T, Kastenmüller A, Weinkauf S, Buchner J. Regulated structural transitions unleash the chaperone activity of aB-crystallin. Proc Natl Acad Sci U S A. 2013 Oct 01; 110(40):E3780-9. PMID: 24043785.
      View in: PubMed
    7. Röhl A, Rohrberg J, Buchner J. The chaperone Hsp90: changing partners for demanding clients. Trends Biochem Sci. 2013 May; 38(5):253-62. PMID: 23507089.
      View in: PubMed
    8. Retzlaff M, Rohrberg J, Küpper NJ, Lagleder S, Bepperling A, Manzenrieder F, Peschek J, Kessler H, Buchner J. The regulatory domain stabilizes the p53 tetramer by intersubunit contacts with the DNA binding domain. J Mol Biol. 2013 Jan 09; 425(1):144-55. PMID: 23103206.
      View in: PubMed
    9. Hagn F, Lagleder S, Retzlaff M, Rohrberg J, Demmer O, Richter K, Buchner J, Kessler H. Structural analysis of the interaction between Hsp90 and the tumor suppressor protein p53. Nat Struct Mol Biol. 2011 Sep 04; 18(10):1086-93. PMID: 21892170.
      View in: PubMed
    10. Rohrberg J, Sachs R, Lodderstedt G, Sackewitz M, Balbach J, Schwarz E. Monitoring fibril formation of the N-terminal domain of PABPN1 carrying an alanine repeat by tryptophan fluorescence and real-time NMR. FEBS Lett. 2008 May 14; 582(11):1587-92. PMID: 18406354.
      View in: PubMed